Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evalute the clinical safety and effectiveness of released specification (2.25mm) of FirehawkTM Sirolimus target-eluting coronary stent system.

Official Title
-----------------
The Safety and Effectiveness Evaluation of New Specifications (2.25mm) of FirehawkTM Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: a Prospective, Multicenter, Single-group Study.

Conditions
-----------------
Coronary Heart Disease

Intervention / Treatment
-----------------
* Device: FirehawkTM 2.25mm


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-80 years of age, males or non-pregnant women; Evidence of silent ischemia, stability or in patients with old myocardial infarction or unstable angina; Primary target lesion, in situ coronary artery disease; Target lesion length ≤ 60mm, target lesion diameter 2.25mm (Visual method); The target lesion diameter stenosis ≥ 70% (Visual method); Each target lesion implantation the same stent (Firehawk stent); With indications for coronary artery bypass surgery; To understand the purpose of testing, voluntary and informed consent, patients agreed to achieve invasive imaging and clinical follow-up. Exclusion Criteria: Within 72h of any acute myocardial infarction; Unprotected left main coronary artery disease, triple vessel lesions which need treated all; bifurcation lesions and vascular lesions of the bridge; Severe calcified lesions that cannot be successfully expanded and distorting lesions not suitable for stent delivery; Artery and/or vein bypass graft lesions; Intracoronary implantation of any branding stents within 1 year; Severe congestive heart failure (NYHA class III and above), or left ventricular ejection fraction <35% (ultrasound or left ventricular angiography); Preoperative renal function serum creatinine >2.0mg/DL; Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy; Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies; The patient's life expectancy is less than 12 months; Top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame; Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements; Heart transplantation patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: new specifications (Diameter 2.25mm)of Firehawk stent<br>Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease | Device: FirehawkTM 2.25mm<br>* Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-stent Late Loss | the difference between the minimal lumen diameter immediately after stent implantation and the minimal lumen diameter by angiography review 9 months after the procedure. | 9 month after stent implantation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Target Lesion Failure | including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization | 12 months | 
| Number of Participants With Target Lesion Failure | including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization | 2 years | 
| Number of Participants With Target Lesion Failure | including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization | 3 years | 
| Number of Participants With Target Lesion Failure | including cardiac death, target vessel myocardial infarction and clinical symptom-driven target lesion revascularization | 4 years | 
| Number of Participants With MACE | a composite endpoint of all cause death, any myocardial infarction and any revascularization | 12 months | 
| Number of Participants With MACE | a composite endpoint of all cause death, any myocardial infarction and any revascularization | 2 years | 
| Number of Participants With MACE | a composite endpoint of all cause death, any myocardial infarction and any revascularization | 3 years | 
| Number of Participants With MACE | a composite endpoint of all cause death, any myocardial infarction and any revascularization | 4 years |